Radiolabeled analog(s) of compound 0118 and use thereof in connection with pet and/or spect imaging to determine whether a pharmaceutical containing compound 0118 is a candidate cancer treatment for a patient

A method for monitoring treatment of cancer with compound 0118, comprising:

• processing image data of a treatment scan performed after at least one treatment with compound 0118 to determine whether a radiolabeled analog of compound 0118 is present in tissue of interest represented in the image data, wherein the presence of the radiolabeled analog of compound 0118 in the tissue of interest indicates presence of a sub-type of cancer having a galectin-1 molecular target, which is a sub-type of treatable by compound 0118;
• and
• generating and presenting a first recommendation signal recommending continuing treatment with compound 0118 in response to the image data of the treatment scan indicating the radiolabeled analog of compound 0118 is present in a predetermined amount in the tissue of interest represented in the image data.

A computing system, comprising:

• a radiotracer identifier that processes at least one of PET or SPECT image data and identifies a presence or absence of a predetermined amount of radiolabeled analog of compound 0118 in tissue of interest of a patient represented in the image data;
• and
• a recommender that generates and visually presents a first recommendation indicating that compound 0118 is a candidate treatment for the patient in response to the radiotracer identifier identifying the presence of the predetermined amount of radiolabeled analog of compound 0118 in tissue of interest of a patient represented in the image data.

A radiotracer, comprising:

• an analog of compound 0118;
• and
• a radiolabel.

A macromolecular structure containing two or more tethered moieties of a non-radioactive analogue of compound 0118 according to formula I:

• wherein the individual calix[4]arene subunits are attached to each other via a linker extending from the equatorial substituent R on the methylene bridge of the calix[4]arene core.